Allogenic adipose-derived mesenchymal stem cell therapy - Regeneus ltdAlternative Names: PRG; Progenza
Latest Information Update: 24 Jun 2015
At a glance
- Originator Regeneus ltd
- Class Antineoplastics; Stem cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Osteoarthritis
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 24 Jul 2015 Phase-I clinical trials in Osteoarthritis in Australia (Intra-articular)